ArticleEuropean archives of psychiatry and clinical neuroscience2022
Further evidence that antipsychotic medication does not prevent long-term psychosis in higher-risk individuals.
Article in European archives of psychiatry and clinical neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- The Effects of Antipsychotics on Two Month Cortical Thickness and Two Year Clinical Outcomes Among Populations at Clinical High Risk for Psychosis.Schizophrenia bulletin · 2026Article
- Cognitive trajectories of psychosis risk: temporal patterns and association with progression.Molecular psychiatry · 2026Article
- Exposure to Antipsychotics in Youths at Clinical High Risk for Psychosis: Low VS High Doses and Their Relevance for Clinical Outcomes.Early intervention in psychiatry · 2026Article
- Availability and effectiveness of multicomponent interventions for early psychosis in 20 low-income and middle-income countries: a systematic review.EClinicalMedicine · 2026Article
- Cytokine changes in clinical high risk for psychosis population following antipsychotic medication.Translational psychiatry · 2026Article
- Timeframe for Conversion to Psychosis From Individuals at Clinical High-Risk: A Quantile Regression.Schizophrenia bulletin · 2025Article
- The impact of aripiprazole on neurocognitive function in individuals at clinical high risk for psychosis: A comparison with olanzapine and non-antipsychotic treatment.European psychiatry : the journal of the Association of European Psychiatrists · 2025Article
- Neurocognitive resilience as a predictor of psychosis onset and functional outcomes in individuals at high risk.BMC medicine · 2025Article
- Advancements and Future Directions in Prevention Based on Evaluation for Individuals With Clinical High Risk of Psychosis: Insights From the SHARP Study.Schizophrenia bulletin · 2025Review
- Subgroups of Clinical High Risk for Psychosis Based on Baseline Antipsychotic Exposure: Clinical and Outcome Comparisons Across a 2-Year Follow-up Period.Schizophrenia bulletin · 2025Article
- Baseline Exposure to Antipsychotic Medication in Young People at Clinical High Risk for Psychosis: A 2-Year Italian Follow-Up Study.Human psychopharmacology · 2025Article
- Cognitive functions following initiation of antipsychotic medication in adolescents and adults at clinical high risk for psychosis: a naturalistic sub group analysis using the MATRICS consensus cognitive battery.Child and adolescent psychiatry and mental health · 2024Article
- Variations to plasma HSchizophrenia (Heidelberg, Germany) · 2024Article
- Duration of Untreated Prodromal Psychosis and Cognitive Impairments.JAMA network open · 2024Article
- Comprehensive review of multidimensional biomarkers in the ShangHai At Risk for Psychosis (SHARP) program for early psychosis identification.PCN reports : psychiatry and clinical neurosciences · 2023Review
- Neonatal phencyclidine as a model of sex-biased schizophrenia symptomatology in adolescent mice.Psychopharmacology · 2023Article
- Serum Levels of Tumor Necrosis Factor-α and Vascular Endothelial Growth Factor in the Subtypes of Clinical High Risk Individuals: A Prospective Cohort Study [Response to Letter].Neuropsychiatric disease and treatment · 2023Article
- Elucidating gut microbiota-hippocampus interactions in emerging psychosis: A new perspective for the development of early interventions for memory impairments.Frontiers in psychiatry · 2023Article
- History of trauma is a critical treatment target for individuals at clinical high-risk for psychosis.Frontiers in psychiatry · 2022Article
- Prediction and Prevention in the Clinical High-Risk for Psychosis Paradigm: A Review of the Current Status and Recommendations for Future Directions of Inquiry.Frontiers in psychiatry · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveAlthough existing guidelines have discouraged use of antipsychotics for general clinical high-risk (CHR) individuals, it is unclear if antipsychotics can prevent psychosis in higher-risk population. We aimed to study the comparative real-world effectiveness of antipsychotic treatments for preventing psychosis in higher-risk CHR individuals.
methodsA total of 300 CHR individuals were identified using the structured interview for prodromal syndromes (SIPS) and followed the participants for 3 years. In total, 228(76.0%) individuals completed baseline assessments using the NAPLS-2 risk calculator (NAPLS-2-RC), and 210(92.1%) completed the follow-up. The sample was further stratified according to risk level. "Higher-risk" was defined based on the NAPLS-2-RC risk score (≥ 20%) and SIPS positive symptom total scores (≥ 10). The main outcome was conversion to psychosis and poor functional outcomes, defined as a global assessment of function (GAF) score lower than 60 at follow-up.
resultsIn higher-risk CHR individuals, we found no significant difference in the rate of conversion to psychosis or poor functional outcomes between the antipsychotic and no-antipsychotic groups. Low-risk individuals treated with antipsychotic drugs were more likely exhibit poor functional outcomes compared with the no-antipsychotics group(NAPLS-2-RC estimated risk: χ
conclusionsIn CHR individuals, antipsychotic treatment should be provided with caution because of the risk of poor functional outcomes. Further, antipsychotic treatment does not appear to prevent onset of psychosis in real-world settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.